Project Grant HT94252411017
Award Date
11/1/24
Completion Date
10/31/27
Dollars Obligated
$838K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Plandome, NY 11030, USA
Similar Awards
This $6,214,900 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the Scintillon Institute to investigate the role of genetic risk factors and immune response on neurovascular unit (NVU) function in post-traumatic brain injury (TBI) cognitive impairment. The 4-year award, effective from November 1, 2024 to October 31, 2028, will enable the Scintillon Institute to conduct advanced biomedical research...
This $309,279 Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research study on traumatic brain injury (TBI) and psychological health conducted by Florida State University. The primary objectives are to adapt the Ohio State University TBI Identification Method and the STAIR-NT intervention for first responders with TBI, analyze the data, and disseminate the study findings. Key sub-award activities...
The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...
The Feinstein Institutes for Medical Research was awarded a $655,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research characterizing immunological and genomic resistance mechanisms to anti-PD-1 immunotherapy in smoking-associated head and neck cancer. The grant period runs from April 15, 2022 to April 14, 2025. Through this funding, the Feinstein Institutes will investigate...
The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $299,937.00 to The Feinstein Institutes For Medical Research to conduct research on visualizing neural synaptic density in systemic lupus erythematosus (SLE) to better understand mechanisms of brain dysfunction. The award period runs from July 15, 2024 to July 14, 2026. The Feinstein Institutes, a non-profit research organization, will utilize this...
This federal Project Grant award, valued at $999,972.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports research by The Feinstein Institutes for Medical Research to study urine macrophages in lupus nephritis in order to shed light on kidney disease processes. This 4-year research project, with a period of performance from July 1, 2025 to June 30, 2029, aims to advance the understanding of...
The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
This federal Project Grant award in the amount of $747,507 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports an evaluation of an engineered calpain activity nanosensor in a mouse model of traumatic brain injury (TBI) at the University of California, San Diego (UCSD). The objective of the research is to advance the development of innovative technologies for monitoring and assessing traumatic brain injuries,...